CSF3 and acute myeloid leukemia: <b>Objective:</b> To compare the efficacy and safety of venetoclax (VEN) combined with azacitidine (AZA) (VA) versus decitabine combined with cytarabine+aclarubicin+granulocyte colony-stimulating factor (CAG) (D-CAG) regimen in the treatment of elderly patients with relapsed or refractory acute myeloid leukemia (RR-AML) .